Statements of Operations - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 4,123,538	$ 4,033,963	$ 2,149,641	$ 6,183,604	$ 10,307,142	$ 16,515,543	$ 8,479,031
General and administrative	2,361,299	1,938,447	3,104,071	5,042,518	7,403,817	8,995,736	6,058,190
Total operating expenses	6,484,837	5,972,410	5,253,712	11,226,122	17,710,959	25,511,279	14,537,221
Operating loss	(6,484,837)	(5,972,410)	(5,253,712)	(11,226,122)	(17,710,959)	(25,511,279)	(14,537,221)
Other income:
Interest income	52,886	36,024	19,649	55,673	108,559	182,712	13,335
Grant income							36,754
Total other income	52,886	36,024	19,649	55,673	108,559	182,712	50,089
Loss before income taxes	(6,431,951)	(5,936,386)	(5,234,063)	(11,170,449)	(17,602,400)	(25,328,567)	(14,487,132)
Income tax expense (benefit)
Net loss	$ (6,431,951)	$ (5,936,386)	$ (5,234,063)	$ (11,170,449)	$ (17,602,400)	$ (25,328,567)	$ (14,487,132)
Basic loss per common share	$ (0.79)	$ (0.73)	$ (0.64)	$ (1.37)	$ (2.16)	$ (3.10)	$ (1.90)
Diluted loss per common share	$ (0.79)	$ (0.73)	$ (0.64)	$ (1.37)	$ (2.16)	$ (3.10)	$ (1.90)
Weighted average number of common shares outstanding, basic	8,163,923	8,163,923	8,157,445	8,160,702	8,161,787	8,162,326	7,626,278
Weighted average number of common shares outstanding, diluted	8,163,923	8,163,923	8,157,445	8,160,702	8,161,787	8,162,326	7,626,278